NKGen Biotech Ownership 2024 | Who Owns NKGen Biotech Now?
Institutional Ownership
31.65%
Insider Ownership
41.42%
Retail Ownership
26.92%
Institutional Holders
13.00
NKGen Biotech Institutional Shareholders
Institutional Shareholders by % of Total Shares
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
JPMORGAN CHASE & CO | - | - | - | -100,557 | -100.00% | - | Dec 31, 2023 |
KARPUS MANAGEMENT, INC. | - | - | - | -280,525 | -100.00% | - | Dec 31, 2023 |
BALYASNY ASSET MANAGEMENT L.P. | - | - | - | -310,359 | -100.00% | - | Dec 31, 2023 |
RIVERNORTH CAPITAL MANAGEMENT, LLC | - | - | - | -580,432 | -100.00% | - | Dec 31, 2023 |
ALBERTA INVESTMENT MANAGEMENT CORP | - | - | - | -200,000 | -100.00% | - | Dec 31, 2023 |
WESTCHESTER CAPITAL MANAGEMENT, LLC | - | - | - | -105,266 | -100.00% | - | Dec 31, 2023 |
MINT TOWER CAPITAL MANAGEMENT B.V. | - | - | - | -200,000 | -100.00% | - | Dec 31, 2023 |
PERISCOPE CAPITAL INC. | - | - | - | -347,994 | -100.00% | - | Dec 31, 2023 |
CLEAR STREET LLC | - | - | - | -73,364 | -100.00% | - | Dec 31, 2023 |
DIAMETRIC CAPITAL, LP | - | - | - | -471,000 | -100.00% | - | Dec 31, 2023 |
SANDIA INVESTMENT MANAGEMENT LP | - | - | - | -471,000 | -100.00% | - | Dec 31, 2023 |
METEORA CAPITAL, LLC | - | - | - | -2,122,715 | -100.00% | - | Dec 31, 2023 |
SPARTAN FUND MANAGEMENT INC. | - | - | - | -62,987 | -100.00% | - | Dec 31, 2023 |
NKGen Biotech's largest institutional shareholder is JPMORGAN CHASE & CO, holding 0.00% of the company's total share outstanding, currently valued at -. The top 10 institutional shareholders own together 0.00% of the company.
Institutional Shareholders by % of Total Assets
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
JPMORGAN CHASE & CO | - | - | - | -100,557 | -100.00% | - | Dec 31, 2023 |
KARPUS MANAGEMENT, INC. | - | - | - | -280,525 | -100.00% | - | Dec 31, 2023 |
BALYASNY ASSET MANAGEMENT L.P. | - | - | - | -310,359 | -100.00% | - | Dec 31, 2023 |
RIVERNORTH CAPITAL MANAGEMENT, LLC | - | - | - | -580,432 | -100.00% | - | Dec 31, 2023 |
ALBERTA INVESTMENT MANAGEMENT CORP | - | - | - | -200,000 | -100.00% | - | Dec 31, 2023 |
WESTCHESTER CAPITAL MANAGEMENT, LLC | - | - | - | -105,266 | -100.00% | - | Dec 31, 2023 |
MINT TOWER CAPITAL MANAGEMENT B.V. | - | - | - | -200,000 | -100.00% | - | Dec 31, 2023 |
PERISCOPE CAPITAL INC. | - | - | - | -347,994 | -100.00% | - | Dec 31, 2023 |
CLEAR STREET LLC | - | - | - | -73,364 | -100.00% | - | Dec 31, 2023 |
DIAMETRIC CAPITAL, LP | - | - | - | -471,000 | -100.00% | - | Dec 31, 2023 |
SANDIA INVESTMENT MANAGEMENT LP | - | - | - | -471,000 | -100.00% | - | Dec 31, 2023 |
METEORA CAPITAL, LLC | - | - | - | -2,122,715 | -100.00% | - | Dec 31, 2023 |
SPARTAN FUND MANAGEMENT INC. | - | - | - | -62,987 | -100.00% | - | Dec 31, 2023 |
The largest NKGen Biotech shareholder by % of total assets is JPMORGAN CHASE & CO. The company owns 0.00 shares of NKGen Biotech (GFOR), representing 0.00% of its total assets.
Institutional Buyers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
SPARTAN FUND MANAGEMENT INC. | - | - | - | -62,987 | -100.00% | - | Dec 31, 2023 |
CLEAR STREET LLC | - | - | - | -73,364 | -100.00% | - | Dec 31, 2023 |
JPMORGAN CHASE & CO | - | - | - | -100,557 | -100.00% | - | Dec 31, 2023 |
WESTCHESTER CAPITAL MANAGEMENT, LLC | - | - | - | -105,266 | -100.00% | - | Dec 31, 2023 |
MINT TOWER CAPITAL MANAGEMENT B.V. | - | - | - | -200,000 | -100.00% | - | Dec 31, 2023 |
ALBERTA INVESTMENT MANAGEMENT CORP | - | - | - | -200,000 | -100.00% | - | Dec 31, 2023 |
KARPUS MANAGEMENT, INC. | - | - | - | -280,525 | -100.00% | - | Dec 31, 2023 |
BALYASNY ASSET MANAGEMENT L.P. | - | - | - | -310,359 | -100.00% | - | Dec 31, 2023 |
PERISCOPE CAPITAL INC. | - | - | - | -347,994 | -100.00% | - | Dec 31, 2023 |
SANDIA INVESTMENT MANAGEMENT LP | - | - | - | -471,000 | -100.00% | - | Dec 31, 2023 |
DIAMETRIC CAPITAL, LP | - | - | - | -471,000 | -100.00% | - | Dec 31, 2023 |
RIVERNORTH CAPITAL MANAGEMENT, LLC | - | - | - | -580,432 | -100.00% | - | Dec 31, 2023 |
METEORA CAPITAL, LLC | - | - | - | -2,122,715 | -100.00% | - | Dec 31, 2023 |
As of Dec 31 2023, NKGen Biotech's largest institutional buyer is SPARTAN FUND MANAGEMENT INC.. The company purchased -62.99K stocks of GFOR, valued at -.
Institutional Sellers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
METEORA CAPITAL, LLC | - | - | - | -2,122,715 | -100.00% | - | Dec 31, 2023 |
RIVERNORTH CAPITAL MANAGEMENT, LLC | - | - | - | -580,432 | -100.00% | - | Dec 31, 2023 |
DIAMETRIC CAPITAL, LP | - | - | - | -471,000 | -100.00% | - | Dec 31, 2023 |
SANDIA INVESTMENT MANAGEMENT LP | - | - | - | -471,000 | -100.00% | - | Dec 31, 2023 |
PERISCOPE CAPITAL INC. | - | - | - | -347,994 | -100.00% | - | Dec 31, 2023 |
BALYASNY ASSET MANAGEMENT L.P. | - | - | - | -310,359 | -100.00% | - | Dec 31, 2023 |
KARPUS MANAGEMENT, INC. | - | - | - | -280,525 | -100.00% | - | Dec 31, 2023 |
ALBERTA INVESTMENT MANAGEMENT CORP | - | - | - | -200,000 | -100.00% | - | Dec 31, 2023 |
MINT TOWER CAPITAL MANAGEMENT B.V. | - | - | - | -200,000 | -100.00% | - | Dec 31, 2023 |
WESTCHESTER CAPITAL MANAGEMENT, LLC | - | - | - | -105,266 | -100.00% | - | Dec 31, 2023 |
JPMORGAN CHASE & CO | - | - | - | -100,557 | -100.00% | - | Dec 31, 2023 |
CLEAR STREET LLC | - | - | - | -73,364 | -100.00% | - | Dec 31, 2023 |
SPARTAN FUND MANAGEMENT INC. | - | - | - | -62,987 | -100.00% | - | Dec 31, 2023 |
As of Dec 31 2023, NKGen Biotech's biggest institutional seller is METEORA CAPITAL, LLC. The company sold -2.12M shares of GFOR, valued at -.
Institutional New positions
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|
Institutional Sold Out
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
METEORA CAPITAL, LLC | - | - | - | -2,122,715 | -100.00% | - | Dec 31, 2023 |
RIVERNORTH CAPITAL MANAGEMENT, LLC | - | - | - | -580,432 | -100.00% | - | Dec 31, 2023 |
DIAMETRIC CAPITAL, LP | - | - | - | -471,000 | -100.00% | - | Dec 31, 2023 |
SANDIA INVESTMENT MANAGEMENT LP | - | - | - | -471,000 | -100.00% | - | Dec 31, 2023 |
PERISCOPE CAPITAL INC. | - | - | - | -347,994 | -100.00% | - | Dec 31, 2023 |
BALYASNY ASSET MANAGEMENT L.P. | - | - | - | -310,359 | -100.00% | - | Dec 31, 2023 |
KARPUS MANAGEMENT, INC. | - | - | - | -280,525 | -100.00% | - | Dec 31, 2023 |
ALBERTA INVESTMENT MANAGEMENT CORP | - | - | - | -200,000 | -100.00% | - | Dec 31, 2023 |
MINT TOWER CAPITAL MANAGEMENT B.V. | - | - | - | -200,000 | -100.00% | - | Dec 31, 2023 |
WESTCHESTER CAPITAL MANAGEMENT, LLC | - | - | - | -105,266 | -100.00% | - | Dec 31, 2023 |
JPMORGAN CHASE & CO | - | - | - | -100,557 | -100.00% | - | Dec 31, 2023 |
CLEAR STREET LLC | - | - | - | -73,364 | -100.00% | - | Dec 31, 2023 |
SPARTAN FUND MANAGEMENT INC. | - | - | - | -62,987 | -100.00% | - | Dec 31, 2023 |
NKGen Biotech's largest sold out institutional shareholder by shares sold is METEORA CAPITAL, LLC, sold -2.12M shares, valued at -, as of undefined.
NKGen Biotech Mutual Fund Holders
Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
---|---|---|---|---|---|
SPECIAL OPPORTUNITIES FUND, INC. | 0.23% | 100,000 | - | - | Mar 31, 2024 |
GABELLI DIVIDEND & INCOME TRUST | 0.08% | 135,000 | - | - | Dec 29, 2023 |
RIVERNORTH OPPORTUNITIES FUND, INC. | 0.04% | 48,320 | - | - | Jan 31, 2024 |
RiverNorth Specialty Finance Corp | 0.02% | 22,295 | 22,295 | - | Sep 30, 2023 |
Saba Capital Income & Opportunities Fund | 0.02% | 55,750 | - | - | Jan 31, 2024 |
SCM Trust | 0.02% | 65,772 | - | - | Dec 31, 2023 |
Investment Managers Series Trust II | 0.02% | 200,201 | - | - | Jan 31, 2024 |
MERGER FUND | 0.01% | 85,305 | - | - | Mar 28, 2024 |
MERGER FUND VL | 0.01% | 1,034 | - | - | Mar 28, 2024 |
Virtus Event Opportunities Trust | 0.00% | 9,192 | - | - | Mar 28, 2024 |
Listed Funds Trust | 0.00% | 10,502 | - | - | Mar 31, 2024 |
FIRST TRUST ALTERNATIVE OPPORTUNITIES FUND | 0.00% | 2,885 | - | - | Dec 31, 2023 |
PRINCIPAL FUNDS, INC. | 0.00% | 1,561 | - | - | Feb 29, 2024 |
NKGen Biotech's largest mutual fund holder by % of total assets is "SPECIAL OPPORTUNITIES FUND, INC.", owning 100.00K shares, compromising 0.23% of its total assets.
NKGen Biotech Institutional Ownership Trends
Institutional Holdings Trend
Date | Holdings | Change % |
---|---|---|
30 Sep, 23 | 13 | -48.00% |
30 Jun, 23 | 25 | -53.70% |
31 Mar, 23 | 54 | -11.48% |
31 Dec, 22 | 61 | 17.31% |
30 Sep, 22 | 52 | 10.64% |
30 Jun, 22 | 47 | 11.90% |
31 Mar, 22 | 42 | 5.00% |
31 Dec, 21 | 40 | 11.11% |
30 Sep, 21 | 36 | - |
As of 30 Sep 23, 13 institutions are holding NKGen Biotech's shares, representing a decrease of -48.00% compared to the previous quarter.
Shares Outstanding Trend
Date | Shares Outstanding | Change % |
---|---|---|
30 Sep, 23 | 5,326,199 | -12.66% |
30 Jun, 23 | 6,098,503 | -62.35% |
31 Mar, 23 | 16,198,501 | 1.70% |
31 Dec, 22 | 15,927,620 | 8.97% |
30 Sep, 22 | 14,616,386 | 15.68% |
30 Jun, 22 | 12,635,460 | 3.44% |
31 Mar, 22 | 12,215,582 | 10.17% |
31 Dec, 21 | 11,087,449 | 17.84% |
30 Sep, 21 | 9,409,113 | - |
NKGen Biotech (GFOR) has 5.33M shares outstanding as of 30 Sep 23, down -12.66% compared to the previous quarter.
Institutional Ownership Trend
Date | Ownership % | Change % |
---|---|---|
30 Sep, 23 | 31.65% | 3.92% |
30 Jun, 23 | 28.43% | 0.50% |
31 Mar, 23 | 75.51% | 1.37% |
31 Dec, 22 | 74.25% | 1.60% |
30 Sep, 22 | 68.14% | 1.96% |
30 Jun, 22 | 58.90% | 1.82% |
31 Mar, 22 | 56.94% | 2.13% |
31 Dec, 21 | 51.69% | 2.69% |
30 Sep, 21 | 43.86% | - |
As of 30 Sep 23, NKGen Biotech is held by 31.65% institutional shareholders, representing a 3.92% growth compared to 30 Jun 23.
Institutional Increased Positions Trend
Date | Increased Positions | Change % |
---|---|---|
30 Sep, 23 | 4 | -50.00% |
30 Jun, 23 | 8 | -38.46% |
31 Mar, 23 | 13 | -56.67% |
31 Dec, 22 | 30 | 76.47% |
30 Sep, 22 | 17 | 41.67% |
30 Jun, 22 | 12 | - |
31 Mar, 22 | 12 | -7.69% |
31 Dec, 21 | 13 | -63.89% |
30 Sep, 21 | 36 | - |
4 institutional shareholders have increased their position in GFOR stock as of 30 Sep 23 compared to 8 in the previous quarter (a -50.00% decrease).
Institutional Reduced Positions Trend
Date | Reduced Positions | Change % |
---|---|---|
30 Sep, 23 | 3 | -72.73% |
30 Jun, 23 | 11 | 37.50% |
31 Mar, 23 | 8 | 33.33% |
31 Dec, 22 | 6 | -25.00% |
30 Sep, 22 | 8 | 700.00% |
30 Jun, 22 | 1 | -66.67% |
31 Mar, 22 | 3 | -40.00% |
31 Dec, 21 | 5 | - |
30 Sep, 21 | - | - |
3 institutional shareholders have reduced their position in GFOR stock as of 30 Sep 23 compared to 11 in the previous quarter (a -72.73% decrease).
All Institutional Ownership Trend Data
Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
---|---|---|---|---|---|---|---|---|---|---|
30 Sep, 23 | 13 | -48.00% | 5,326,199 | -12.66% | 31.65% | 3.92% | 4 | -50.00% | 3 | -72.73% |
30 Jun, 23 | 25 | -53.70% | 6,098,503 | -62.35% | 28.43% | 0.50% | 8 | -38.46% | 11 | 37.50% |
31 Mar, 23 | 54 | -11.48% | 16,198,501 | 1.70% | 75.51% | 1.37% | 13 | -56.67% | 8 | 33.33% |
31 Dec, 22 | 61 | 17.31% | 15,927,620 | 8.97% | 74.25% | 1.60% | 30 | 76.47% | 6 | -25.00% |
30 Sep, 22 | 52 | 10.64% | 14,616,386 | 15.68% | 68.14% | 1.96% | 17 | 41.67% | 8 | 700.00% |
30 Jun, 22 | 47 | 11.90% | 12,635,460 | 3.44% | 58.90% | 1.82% | 12 | - | 1 | -66.67% |
31 Mar, 22 | 42 | 5.00% | 12,215,582 | 10.17% | 56.94% | 2.13% | 12 | -7.69% | 3 | -40.00% |
31 Dec, 21 | 40 | 11.11% | 11,087,449 | 17.84% | 51.69% | 2.69% | 13 | -63.89% | 5 | - |
30 Sep, 21 | 36 | - | 9,409,113 | - | 43.86% | - | 36 | - | - | - |
NKGen Biotech Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
Insider Sells
All Insider Owners Trades
The last insider sell of NKGen Biotech's stock was made by Park Sangwoo on Dec 15 2023, selling 2,500,000 shares at - per share (valued at -). The last insider buy of GFOR was made by Song Paul Y. on Dec 07 2023, buying 76 shares at $3.29 per share (worth $250.24).
NKGen Biotech Insider Ownership Trends
All Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q4 2023 | 12 | 1 | 1200.00% |
Q3 2023 | 2 | 8 | 25.00% |
Q2 2022 | - | - | - |
Q3 2021 | - | 2 | - |
Q2 2021 | 10 | 5 | 200.00% |
12 total buy trades, and 1 total sell trades (buy/sell ratio of 12.00%) were made by NKGen Biotech's insiders, as of Q4 2023.
Open Market Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q4 2023 | 12 | - | - |
Q3 2023 | - | - | - |
Q2 2022 | - | - | - |
Q3 2021 | - | - | - |
Q2 2021 | 10 | - | - |
As of Q4 2023, Insider owners conducted 12 open market buy trades and 0 open market sell trades of NKGen Biotech's stocks.
GFOR Ownership FAQ
Who Owns NKGen Biotech?
NKGen Biotech is owned by institutional shareholders (31.65%), insiders (41.42%), and public (26.92%). The largest institutional shareholder of NKGen Biotech is JPMORGAN CHASE & CO (0% of total shares) and the top mutual fund owner is SPECIAL OPPORTUNITIES FUND, INC. (0.23% of total shares).
Who are the major institutional shareholders of NKGen Biotech?
NKGen Biotech's major institutional shareholders are JPMORGAN CHASE & CO, KARPUS MANAGEMENT, INC., BALYASNY ASSET MANAGEMENT L.P., RIVERNORTH CAPITAL MANAGEMENT, LLC, and ALBERTA INVESTMENT MANAGEMENT CORP. The top five shareholders own together 0% of the company's share outstanding.
How many NKGen Biotech shareholders are there?
As of Sep 2023, there are 13 institutional shareholders of NKGen Biotech.
What percentage of NKGen Biotech is owned by JPMORGAN CHASE & CO?
JPMORGAN CHASE & CO owns 0 shares of NKGen Biotech, representing 0% of the company's total shares outstanding, valued at $0 (as of Dec 2023).
What percentage of NKGen Biotech is owned by KARPUS MANAGEMENT, INC?
As of Dec 2023, KARPUS MANAGEMENT, INC holds 0 shares of NKGen Biotech (GFOR), compromising 0% of the company, valued at $0.
What percentage of NKGen Biotech is owned by BALYASNY ASSET MANAGEMENT L.P?
BALYASNY ASSET MANAGEMENT L.P is the third largest holder of NKGen Biotech. The company owns 0 of the company's shares outstanding (worth $0).